Literature DB >> 23394553

Statin intolerance: why and what to do - with a focus on diabetic people.

E Matteucci1, O Giampietro.   

Abstract

The standards of medical care in diabetes recommend that statin therapy is added to lifestyle therapy for diabetic patients with overt cardiovascular disease (LDL cholesterol goal <70 mg/dl), or without cardiovascular disease who are over the age of 40 years and who have one or more other cardiovascular disease risk factors (LDL cholesterol goal <100 mg/dl). In order to reach strict LDL targets, high doses of statins may be required. However, the frequency of statin associated adverse effects and statin intolerance in clinical practice is high (up to 10-15% of statin users) especially at muscle level. The review overviews: 1) the known or hypothesised mechanisms through which causal and contributing factors are associated with adverse effects in diabetic people, and 2) the rationale of strategies for managing statin intolerant patients.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23394553     DOI: 10.2174/0929867311320110004

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  4 in total

Review 1.  Demystifying the management of hypertriglyceridaemia.

Authors:  Gerald F Watts; Esther M M Ooi; Dick C Chan
Journal:  Nat Rev Cardiol       Date:  2013-09-24       Impact factor: 32.419

Review 2.  G-Protein-coupled receptors as potential drug candidates in preeclampsia: targeting the relaxin/insulin-like family peptide receptor 1 for treatment and prevention.

Authors:  Kirk P Conrad
Journal:  Hum Reprod Update       Date:  2016-07-06       Impact factor: 15.610

3.  Development and Content Validity of the Statin Experience Assessment Questionnaire (SEAQ)©.

Authors:  Terry A Jacobson; Steven V Edelman; Nina Galipeau; Alan L Shields; Usha G Mallya; Andrew Koren; Michael H Davidson
Journal:  Patient       Date:  2017-06       Impact factor: 3.883

4.  Pharmacologic inhibition of sphingomyelin synthase (SMS) activity reduces apolipoprotein-B secretion from hepatocytes and attenuates endotoxin-mediated macrophage inflammation.

Authors:  Bin Lou; Jibin Dong; Yali Li; Tingbo Ding; Tingting Bi; Yue Li; Xiaodong Deng; Deyong Ye; Xian-Cheng Jiang
Journal:  PLoS One       Date:  2014-07-17       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.